Latest news

• Gilead files hepatitis C salvage regimen in US

  It also worked in patients who had failed earlier treatments that included NS5A inhibitor drugs such as Gilead's ledipasvir and velpatasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and

• NICE backs three hepatitis C meds, turns down Duchenne drug

  NICE issued positive final draft guidance for Gilead's Harvoni (sofosbuvir/ledipasvir), BMS' Daklinza (daclatasvir) and AbbVie's Viekirax (ombitasvir/paritaprevir/ritonavir), with or without Exviera (dasabuvir), making the new drugs

• First-ever World Hepatitis Summit calls for national programmes

  Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two

• Access to new hep C treatments put under the spotlight

  As World Hepatitis Day draws to a close, Bristol-Myers Squibb has hit back at NICE's decision to restrict use of its new hepatitis C treatment Daklinza (daclatasvir) to a

• FDA approves four new medicines across multiple areas

  Hepatitis C. Finally, Bristol-Myers Squibb's hepatitis C drug Daklinza (daclatasvir) has been approved by the FDA as a combination treatment with Gilead's blockbuster pill Sovaldi (sofosbuvir) to treat